Online inquiry

IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5616MR)

This product GTTS-WQ5616MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5616MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ685MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ3715MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ5556MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ2695MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ10840MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ10151MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ866MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ5864MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW